Physician Investigator (Cl) Neurological Clinical Research Institute, Mass General Research Institute

Instructor in Neurology Harvard Medical School

Assistant In Neurology Neurology-N/A, Massachusetts General Hospital

B.S. Stanford University 2011

MD Perelman School of Medicine at the Univeristy of Pennsylvania 2016

als biomarkers; amyotrophic lateral sclerosis Mark Garret is a neurologist and neuromuscular specialist focused on advancing clinical therapies for patients with amyotrophic lateral sclerosis (ALS). Since joining faculty at MGH, his research efforts have focused on the development and validation of biomarkers for ALS with a focus on defining presymptomatic disease stages of ALS. In conjunction with Dr. James Berry, he runs the Dominantly Inherited ALS Network (DIALS) / PREVENT ALS study, a large observational study of asymptomatic carriers for ALS disease causing genes. He leads multiple observational studies focused on biofluid and electrodaignostic biomarker development for ALS. He is also active as a clinical trialist focused on translating gene targeted therapies for familial ALS into clinical practice including work as site PI for the ATLAS trial of BIIB067 (tofersen) in SOD1 ALS gene carriers, the first trial of gene targeted therapy in pre-symptomatic ALS gene carriers.